07:26 AM EST, 12/30/2024 (MT Newswires) -- Chimerix ( CMRX ) said Monday it has submitted a new drug application with the US Food and Drug Administration for the accelerated approval of its experimental drug, dordaviprone, which is intended to treat a type of tumor caused by a mutation in the histone 3 gene.

The company said it has requested a priority review, which could lead to a decision by Q3 2025.

Chimerix ( CMRX ) also said it has entered an amended loan agreement with Silicon Valley Bank for up to $30 million.

The agreement allows the company to draw up to $20 million through February 2026, with an additional $10 million available upon approval through February 2027.